PARP1 and diffuse large B-cell lymphoma: Rituximab directly inhibits subunits of the NF-κB pathway [53] and might therefore lead to accumulation of more damage in ABC-type DLBCL that depends on high PARP1 expression for repair and NF-κB activation.